Pragmatic Comparative Effectiveness Trials in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Both expert and patient panels endorsed using real-world clinical outcomes and patient-reported outcomes as primary trial end points. Pragmatic trials could reduce costs and expand inclusion criteria, highlighting the potential of patient-centered approaches in RA-ILD research.
Authors
- Scott M. Matson (ORCID: https://orcid.org/0000-0002-3748-9597)
- Elizabeth R. Volkmann (ORCID: https://orcid.org/0000-0003-3750-6569)
- Joshua J. Solomon (ORCID: https://orcid.org/0000-0001-5488-4874)
- R. Boente (ORCID: https://orcid.org/0000-0003-3750-1311)
- Dinesh Pal Mudaranthakam (ORCID: https://orcid.org/0000-0001-9767-1158)
- C. Streiler (ORCID: https://orcid.org/0000-0001-7661-6491)
- Ayodeji Adegunsoye (ORCID: https://orcid.org/0000-0002-7015-9610)
- Janell Reichuber
- Bryant R. England (ORCID: https://orcid.org/0000-0002-9649-3588)
- Susan K. Mathai (ORCID: https://orcid.org/0000-0002-5899-8083)
- Jeff Swigris
- Sahil Pandya
- Angela Kaczorowski-Worthley (ORCID: https://orcid.org/0000-0001-7251-9168)
Institutions
- University of Kansas (US)
- University of California, Los Angeles (US)
- Baylor University Medical Center (US)
- National Jewish Health (US)
- University of Chicago (US)
- University of Kansas Medical Center (US)
- VA Nebraska Western Iowa Health Care System (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- University of Missouri–Kansas City (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- CHEST Pulmonary
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1016/j.chpulm.2025.100159
- Citations
- 2
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 3.04